We randomly selected four additional genes (AKT2, AKT3 GRB2 and MMP2) from the “glioma” pathway, other than the validated targets of the key miRNAs.to check for downstream effect of miRNA overexpression. The gene discussed is GRB2; the disease is central nervous system cancer.